SDZ 51641 is an orally active fatty acid oxidation inhibitor. By reducing fatty acid oxidation, SDZ 51641 deprives the gluconeogenesis process of required energy and cofactors, thereby lowering blood glucose levels in diabetic models. SDZ 51641 can be used in diabetes research.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > Others | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Drug Intermediate
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye